0001040130FALSE00010401302024-04-152024-04-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 6, 2024
PetMed Express, Inc.
(Exact name of registrant as specified in its charter)
Florida
000-28827
65-0680967
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
420 South Congress Avenue, Delray Beach, Florida 33445
(Address of principal executive offices) (Zip Code)
(561) 526-4444
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
PETS
 NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02 Results of Operations and Financial Condition.

On August 6, 2024, PetMed Express, Inc. (the “Company”) issued a press release announcing its June 30, 2024 first quarter of fiscal year 2025 financial results and other financial information, and that management would review these results in a conference call at 4:30 pm Eastern time on August 6, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such filing.
The Company is making reference to non-GAAP financial information in both the press release and the conference call. A reconciliation of these non-GAAP financial measures to the nearest comparable GAAP financial measures is contained in the attached press release.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
99.1 – Press release dated August 6, 2024.
104 – Cover Page Interactive Data File (formatted as Inline XBRL).
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated August 6, 2024
104
Cover Page Interactive Data File (formatted as Inline XBRL)
2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 6, 2024
PETMED EXPRESS, INC.
By:/s/ Sandra Y. Campos
Name:
Sandra Y. Campos
Title:
Chief Executive Officer and President
3

Exhibit 99.1
PetMeds® Announces Fiscal 2025 First Quarter Financial Results

Net Income for first quarter fiscal 2025 was $3.8 million or $0.18 diluted earnings per share


Delray Beach, Florida, August 6, 2024, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2024.


Quarterly Highlights for Q1, Fiscal 2025

•Net sales were $68 million, (13)% lower than the prior year comparable quarter.

•Net income was $3.8 million, or $0.18 diluted earnings per share. This compares to net loss of $(1.1) million, or $(0.06) diluted earnings per share, for the prior year comparable quarter.

•Increase in net income is primarily attributed to a $8.7 million reversal of accumulated stock compensation expense associated with departure of the former CEO, offset by lower gross profit of $4.6 million.

•Adj. EBITDA of $(1.5) million was $4.9 million lower than prior year comparable quarter driven by lower sales and associated gross profit.

“Q1 FY‘25 results reflect a transition quarter as we position the Company for future profitable growth by optimizing our cost structure and leaning into our many customer-centric attributes. During the first quarter, we saw a changeover of the CEO and other key executives,” said Sandra Campos, CEO & President. “May marked my first full month in the CEO role, and in May and June we added a new Chief Marketing Officer, Chief Operating Officer and Chief Digital and Technology Officer, along with two new board members. As mentioned during the Q4 FY‘24 earnings results, this new team is taking significant action in areas that will reposition PETS for growth and profitability.”

“To be clear, the Q1 financial results do not reflect the full impact of these improvements which began in the back half of the quarter,” Ms. Campos continued. “We have made strong progress on key cost reduction initiatives including combining and streamlining operations between PetMeds and PetCareRx, and the new team has begun to advance our customer growth strategies. We are gaining momentum and seeing early positive signs of our key leading indicators, validating our strategy to create an ecosystem of products and services for pets’ well-being and longevity.”

This afternoon the Company will host a conference call to review the quarter’s financial results.

Time: 4:30 P.M. Eastern Time, August 6, 2024

Public call dial in (844) 826-3035 (toll free) or (412) 317-5195.

Webcast stream link: https://investors.petmeds.com for those who wish to stream the call via webcast.

Replay: Available until August 20, 2024, at 11:59 P.M Eastern Time.

To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 10190753.


About PetMed Express, Inc.

Founded in 1996, PetMeds is the leader in pioneering the digital pet pharmacy industry. As a national online retailer, PetMeds.com and PetCareRx.com are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth
Exhibit 99.1 Page 1 of 7

and insurance partnerships, they offer value and convenience to pet families at every stage of their pets' lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, www.PetMeds.com and www.PetCareRx.com.

Forward Looking Statement

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.


PETMEDS INVESTOR RELATIONS CONTACT

ICR, LLC
John Mills
(646) 277-1254

Reed Anderson
(646) 277-1260
investor@petmeds.com


Exhibit 99.1 Page 2 of 7

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except for share and per share data)
June 30,
2024		March 31,
2024
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$45,992 $55,296 
Accounts receivable, less allowance for doubtful accounts of $109 and $273, respectively
2,261 3,283 
Inventories - finished goods25,520 28,556 
Prepaid expenses and other current assets3,851 6,325 
Prepaid income taxes– 188 
Total current assets77,624 93,648 
Noncurrent assets:
Property and equipment, net26,109 26,657 
Intangible and other assets, net16,014 16,503 
Goodwill26,658 26,658 
Operating lease right-of-use assets, net1,297 1,432 
Deferred tax assets, net5,012 4,986 
Total noncurrent assets75,090 76,236 
Total assets$152,714 $169,884 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable$24,467 $37,024 
Sales tax payable25,331 25,012 
Accrued expenses and other current liabilities5,201 7,060 
Current lease liabilities438 459 
Deferred revenue2,146 2,603 
Income taxes payable717 – 
Total current liabilities58,300 72,158 
Long-term lease liabilities883 995 
Total liabilities59,183 73,153 
Commitments and contingencies
Shareholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share
9 9 
Common stock, $0.001 par value, 40,000,000 shares authorized; 20,600,652 and 21,148,692 shares issued and outstanding, respectively
21 21 
Additional paid-in capital16,942 25,146 
Retained earnings76,559 71,555 
Total shareholders' equity93,531 96,731 
Total liabilities and shareholders' equity$152,714 $169,884 
Exhibit 99.1 Page 3 of 7

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except for share and per share amounts) (Unaudited)

Three Months Ended
June 30,

20242023
Sales$67,952 $78,244 
Cost of sales49,981 55,718 
Gross profit17,971 22,526 
Operating expenses:
General and administrative (including stock compensation of ($8,204) and $1,760, respectively)4,874 15,711 
Advertising6,990 7,265 
Depreciation and amortization1,721 1,678 
Total operating expenses13,585 24,654 
Income (loss) from operations4,386 (2,128)
Other income:
Interest income, net95 194 
Other, net231 506 
Total other income326 700 
Income (loss) before provision for income taxes4,712 (1,428)
Provision (benefit) for income taxes958 (292)
Net income (loss) $3,754 $(1,136)
Net income (loss) per common share:
Basic$0.18 $(0.06)
Diluted$0.18 $(0.06)
Weighted average number of common shares outstanding:
Basic20,513,28120,332,526
Diluted20,941,50520,332,526
Cash dividends declared per common share$— $0.30 
Exhibit 99.1 Page 4 of 7

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) (Unaudited)

Three Months Ended
June 30,
20242023
Cash flows from operating activities:
Net income (loss)$3,754 $(1,136)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization1,721 1,678 
Share based compensation(8,204)1,760 
Deferred income taxes(26)(627)
Bad debt expense142 19 
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable880 (46)
Inventories - finished goods3,036 (10,185)
Prepaid income taxes188 335 
Prepaid expenses and other current assets2,474 (2,390)
Operating lease right-of-use assets, net135 196 
Accounts payable(12,558)9,115 
Sales tax payable319 500 
Accrued expenses and other current liabilities(505)1,295 
Lease liabilities(133)(205)
Deferred revenue(457)253 
Income taxes payable717 – 
Net cash (used in) provided by operating activities
$(8,517)$562 
Cash flows from investing activities:
Acquisition of PetCareRx, net of cash acquired– (35,859)
Purchases of property and equipment(683)(1,153)
Net cash used in investing activities$(683)$(37,012)
Cash flows from financing activities:
Dividends paid(104)(6,102)
Net cash used in financing activities$(104)$(6,102)
Net decrease in cash and cash equivalents(9,304)(42,552)
Cash and cash equivalents, at beginning of period55,296 104,086 
Cash and cash equivalents, at end of period$45,992 $61,534 
Supplemental disclosure of cash flow information:
Cash paid for income taxes$81 $– 
Dividends payable in accrued expenses and other current liabilities$112 $1,507 
Exhibit 99.1 Page 5 of 7

Non-GAAP Financial Measures
To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.
We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.
We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
•Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
•Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
•Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
•Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
•Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
•Adjusted EBITDA does not reflect certain expenses including the estimated state sales tax accrual which reduces cash available to us.
•Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.
Exhibit 99.1 Page 6 of 7

Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated:
Reconciliation of Non-GAAP Measures
PetMed Express, Inc.
(Unaudited)
Three Months Ended
Increase (Decrease)
($ in thousands, except percentages)June 30,
2024		June 30,
2023
$
%



Consolidated Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA:



Net income ( loss)$3,754 $(1,136)$4,890 (430)%
Add (subtract):
Share-based Compensation (1)
$(8,204)$1,760 $(9,964)(566)%
Income Taxes$958 $(292)$1,250 (428)%
Depreciation and Amortization$1,721 $1,678 $43 3 %
Interest Income, Net (2)
$(95)$(194)$99 (51)%
Acquisition/Partnership Transactions and Other Items$180 $1,126 $(946)(84)%
Employee Severance$149 $393 $(244)(62)%
Adjusted EBITDA$(1,537)$3,335 $(4,872)(146)%
(1) In April 2024, the Company and its former CEO entered into a Transition and Separation Agreement pursuant to which the Company cancelled the 510,000 restricted shares with a market condition and accelerated vesting on the 30,000 remaining unvested time-restricted shares which otherwise would not have vested. Cancellation and acceleration of these shares resulted in an $8.7 million reduction of compensation expense in the three months ended June 30, 2024.
(2) Included in interest income, net is $410 thousand of interest expense related to the sales tax liability and $505 thousand of interest income for the three months ended June 30, 2024. This compares to $426 thousand of interest expense related to the sales tax liability and $620 thousand of interest income for the three months ended June 30, 2023.

Exhibit 99.1 Page 7 of 7
v3.24.2.u1
Cover
Apr. 15, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 06, 2024
Entity Registrant Name PetMed Express, Inc.
Entity Incorporation, State or Country Code FL
Entity File Number 000-28827
Entity Tax Identification Number 65-0680967
Entity Address, Address Line One 420 South Congress Avenue
Entity Address, City or Town Delray Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33445
City Area Code 561
Local Phone Number 526-4444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol PETS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001040130
Amendment Flag false
PetMed Express (NASDAQ:PETS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas PetMed Express.
PetMed Express (NASDAQ:PETS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas PetMed Express.